Agios Pharma (AGIO) Price & Analysis

Compare

649 Followers

AGIO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$23.42 - $62.58

Previous CloseN/A

Volume212.48K

Average Volume (3M)716.40K

Market Cap

$2.36B

Enterprise Value$1.04B

Total Cash (Recent Filing)$938.94M

Total Debt (Recent Filing)$48.76M

Price to Earnings (P/E)3.7

Beta1.68

Next Earnings

Oct 30, 2025

EPS Estimate

-1.9

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.93

Shares Outstanding58,101,517

10 Day Avg. Volume522,721

30 Day Avg. Volume716,404

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.21

Price to Sales (P/S)51.14

P/FCF Ratio-4.77

Enterprise Value/Market Cap0.44

Enterprise Value/Revenue25.36

Enterprise Value/Gross Profit29.80

Enterprise Value/Ebitda-2.34

Forecast

1Y Price Target

$51.33

Price Target Upside25.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe sNDA remains supported by positive results from the Phase 3 ENERGIZE and ENERGIZE-T trials.

Market SentimentBroad approval in Saudi Arabia without additional requirements has been viewed positively by many investors regarding US approval.

Potential ApprovalThe PDUFA extension suggests the FDA is likely to approve mitapivat in thalassemia after agreeing on the appropriate mitigation strategy.

Bears Say

Commercial UncertaintyThe company did not provide details about the REMS or other ongoing labeling discussions, making the commercial implications hard to assess.

Regulatory DelayThe extension of the PDUFA date was due to concerns about hepatocellular injury, leading to a decrease in stock price.

Agios Pharma News

Agios Pharmaceuticals falls -13.3%

Agios Pharmaceuticals (AGIO) is down -13.3%, or -$5.40 to $35.21. Published first on TheFly – the ultimate source...

1M ago

AGIO

H.C. Wainwright still confident in approval of Agios’ Pyrukynd despite delay

After Agios Pharmaceuticals (AGIO) announced that the FDA has extended the PDUFA goal date for the supplemental New...

1M ago

AGIO

Agios Pharmaceuticals price target lowered to $51 from $52 at BofA

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $51 from $52 and keeps a Buy...

1M ago

AGIO

Agios Pharmaceuticals falls -14.4%

Agios Pharmaceuticals (AGIO) is down -14.4%, or -$5.86 to $34.75. Published first on TheFly – the ultimate source...

1M ago

AGIO

Agios Pharmaceuticals provides update on U.S. PDUFA goal date for PYRUKYND

Agios Pharmaceuticals (AGIO) announced that the U.S. Food and Drug Administration, FDA, has extended the Prescription Drug User...

1M ago

AGIO

Positive Outlook for Agios Pharma Despite Recent Patient Deaths Unrelated to Pyrukynd Treatment

Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on Agios Pharma, retaining the price target of...

2M ago

AGIO

Agios Pharmaceuticals reports Pyrukynd approval by Saudi Food and Drug Authority

Agios Pharmaceuticals (AGIO) announced that the Saudi Food and Drug Authority has approved Pyrukynd for the treatment of...

2M ago

AGIO

Agios Pharma’s PYRUKYND Approved by Saudi Authority

An update from Agios Pharma ( ($AGIO) ) is now available. Agios Pharmaceuticals addressed a recent securities analyst...

2M ago

AGIO

Leerink says Agios pressure related to deaths listed in FAERS database

Leerink analyst Andrew Berens notes that Agios Pharmaceuticals (AGIO) shares were under pressure on Friday, which the firm...

2M ago

AGIO

Agios evaluating fourth Pyrukynd case after analyst report

Agios Pharmaceuticals (AGIO) disclosed in a regulatory filing that it is aware of the securities analyst report published...

2M ago

AGIO

Agios Pharmaceuticals falls -17.8%

Agios Pharmaceuticals (AGIO) is down -17.8%, or -$6.22 to $28.78. Published first on TheFly – the ultimate source...

2M ago

AGIO

Agios Pharmaceuticals falls -22.9%

Agios Pharmaceuticals (AGIO) is down -22.9%, or -$8.00 to $27.00. Published first on TheFly – the ultimate source...

2M ago

AGIO

Agios Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

Agios Pharmaceuticals (($AGIO)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

AGIO

Agios Pharma’s Promising Growth: Buy Rating Backed by Strong Drug Performance and Strategic Focus

Analyst Alec Stranahan of Bank of America Securities reiterated a Buy rating on Agios Pharma, reducing the price...

2M ago

AGIO

AGIO FAQ

What was Agios Pharmaceuticals’s price range in the past 12 months?

Agios Pharmaceuticals lowest stock price was $23.41 and its highest was $62.58 in the past 12 months.

What is Agios Pharmaceuticals’s market cap?

Agios Pharmaceuticals’s market cap is $2.36B.

When is Agios Pharmaceuticals’s upcoming earnings report date?

Agios Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 15 days.

How were Agios Pharmaceuticals’s earnings last quarter?

Agios Pharmaceuticals released its earnings results on Jul 31, 2025. The company reported -$1.93 earnings per share for the quarter, missing the consensus estimate of -$1.807 by -$0.123.

Is Agios Pharmaceuticals overvalued?

According to Wall Street analysts Agios Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Agios Pharmaceuticals pay dividends?

Agios Pharmaceuticals does not currently pay dividends.

What is Agios Pharmaceuticals’s EPS estimate?

Agios Pharmaceuticals’s EPS estimate is -1.9.

How many shares outstanding does Agios Pharmaceuticals have?

Agios Pharmaceuticals has 58,101,517 shares outstanding.

What happened to Agios Pharmaceuticals’s price movement after its last earnings report?

Agios Pharmaceuticals reported an EPS of -$1.93 in its last earnings report, missing expectations of -$1.807. Following the earnings report the stock price went down -0.852%.

Which hedge fund is a major shareholder of Agios Pharmaceuticals?

Currently, no hedge funds are holding shares in AGIO

Agios Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

64.05%

Trailing 12-Months

Asset Growth

90.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Agios Pharma (AGIO) Earnings & Revenues

Historic Earnings Reports

AGIO Company Deck

AGIO Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a generally positive outlook with strong revenue growth for PYRUKYND, advancements in regulatory approvals, and strategic partnerships to expand global reach. However, there were also concerns about revenue variability, increased expenses, and challenges in market expansion, which could temper expectations. Overall, the highlights outweigh the lowlights, suggesting a positive sentiment.View all AGIO earnings summaries

AGIO Stock 12 Month Forecast

Average Price Target

$51.33

▲(25.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","36":"$36","46":"$46","56":"$56","66":"$66"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$39.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,36,46,56,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.25,41.23076923076923,43.21153846153846,45.19230769230769,47.17307692307692,49.15384615384615,51.13461538461539,53.11538461538461,55.09615384615385,57.07692307692308,59.05769230769231,61.03846153846154,63.019230769230774,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.25,40.17923076923077,41.10846153846154,42.03769230769231,42.966923076923074,43.896153846153844,44.825384615384614,45.754615384615384,46.683846153846154,47.61307692307692,48.54230769230769,49.47153846153846,50.40076923076923,{"y":51.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.25,39.23076923076923,39.21153846153846,39.19230769230769,39.17307692307692,39.15384615384615,39.13461538461539,39.11538461538461,39.09615384615385,39.07692307692308,39.05769230769231,39.03846153846154,39.01923076923077,{"y":39,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.91,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.47,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.87,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.87,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.39,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.63,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.37,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.25,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >